吡非尼酮治疗特发性肺纤维化的真实世界体验
该回顾性病例对照研究纳入47例接受吡非尼酮至少12个月的IPF患者与47例未用药对照,发现吡非尼酮组6个月和12个月时FVC%较基线变化优于对照组,不良反应常见但均未中断治疗。
要点
- 吡非尼酮治疗6个月可改善或稳定FVC%和D(L)CO%,优于未用药对照。
- 治疗12个月时FVC%仍优于对照,但D(L)CO%差异无统计学意义。
- 不良反应常见(63.8%),以胃肠道和皮肤反应为主,均未停药。
核心结论
- 真实世界中吡非尼酮治疗12个月对轻至重度IPF患者的肺功能有较好效果。
- 不良反应常见但轻微,患者耐受良好。
研究设计与样本
- 回顾性病例对照研究,连续纳入北京朝阳医院接受吡非尼酮至少12个月的IPF患者47例(吡非尼酮组)。
- 同期未接受吡非尼酮治疗的IPF患者47例为对照组。
- 吡非尼酮组男44例、女3例,年龄48~82岁,平均(66±9)岁;对照组均为男性,年龄51~83岁,平均(67±8)岁。
主要发现
- 随访6个月,吡非尼酮组FVC%较基线变化(3.5±7.2)%,对照组(-2.3±6.7)%(t=2.166,P=0.041)。
- 随访6个月,吡非尼酮组D(L)CO%较基线变化(1.1±6.1)%,对照组(-4.7±6.2)%(t=2.519,P=0.018)。
- 随访12个月,吡非尼酮组FVC%较基线变化(2.3±7.0)%,对照组(-3.3±6.2)%(t=2.292,P=0.030)。
- 随访12个月,吡非尼酮组D(L)CO%较基线变化(-1.3±12.2)%,对照组(-5.3±9.8)%(t=1.047,P=0.303)。
- 吡非尼酮组中17例规律随访者,治疗前6个月FVC%变化(-6.0±8.2)%,治疗后6个月变化(3.9±7.8)%(Z=-2.897,P=0.004);D(L)CO%变化分别为(-7.0±13.3)%和(1.3±6.6)%(Z=-2.151,P=0.031)。
关键数值与推荐
- 以6个月内FVC%较基线下降≥5%或≥10%为界值,治疗后6个月患者下降≥5%或≥10%的例数显著减少(P=0.010、0.018)。
- 吡非尼酮治疗期间30例(63.8%)出现不良反应,其中胃肠道不良反应14例、皮肤不良反应11例,所有患者均未中断治疗。
临床怎么用
- 真实世界中吡非尼酮可用于轻至重度IPF患者,有助于延缓肺功能下降。
- 用药期间需关注胃肠道和皮肤不良反应,但多数患者可耐受并继续治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of pirfenidone (PFD) in idiopathic pulmonary fibrosis (IPF) in real-life world. Methods: 47 consecutive patients with IPF taking PFD for at least 12 months (PFD group) were included for analysis, with 47 patients with IPF who did not take PFD as controls. Data were collected from clinical charts to evaluate the lung function parameters and the adverse reactions of PFD. Results: In the PFD group, the percent predicted forced vital capacity (FVC%) and diffusing capacity of carbon monoxide (D(L)CO%) increased by (3.5±7.2)% and (1.1±6.1)% after 6 months of PFD treatment compared with the baseline, while the mean decline of FVC% and D(L)CO% was(2.3±6.7)% and (4.7±6.2)% in the controls (t=2.166, P=0.041; t=2.519, P=0.018). After 12 months of treatment, FVC% increased by (2.3±7.0)% and D(L)CO% decreased by(1.3±12.2)% compared with the baseline, while the mean decline of FVC% and D(L)CO% was (3.3±6.2)% and (5.3±9.8)% in the controls (t=2.292, P=0.030; t=1.047, P=0.303). In the PFD group, 17 patients regularly received pulmonary function test per 6 months. The mean decline in FVC% and D(L)CO% was(6.0±8.2)% and(7.0±13.3)% from 6 month before treatment to baseline when PFD was started, while the FVC% increased by (3.9±7.8)% and D(L)CO% increased by(1.3±6.6)% after 6 months of treatment compared with the baseline (Z=-2.897, P=0.004; Z=-2.151, P=0.031). The proportion of patients with more than 5% or 10% decline in FVC% decreased significantly after 6 months therapy (P=0.010 and 0.018, respectively). Adverse events were commonly seen in 30 patients while taking pirfenidone. The most common adverse events were gastrointestinal symptoms and skin reactions. Conclusions: In real-life world, PFD therapy for 12 months showed good effectiveness on pulmonary functions in patients with mild to severe IPF. Adverse events were common but mild. 目的: 观察真实世界中吡非尼酮治疗特发性肺纤维化(IPF)的疗效和安全性。 方法: 采用回顾性病例对照研究的方法连续入选北京朝阳医院接受吡非尼酮治疗的IPF患者47例(吡非尼酮组),其中男44例,女3例,年龄48~82岁,平均(66±9)岁;同期未接受吡非尼酮治疗的IPF患者47例(对照组),均为男性,年龄51~83岁,平均(67±8)岁。按照研究流程记录临床数据,观察吡非尼酮的疗效及不良反应,并进行定期随访。 结果: 随访6个月时吡非尼酮组与对照组FVC占预计值%较基线变化值分别为[(3.5±7.2)%和(-2.3±6.7)%,t=2.166,P=0.041);D(L)CO占预计值%较基线变化值分别为[(1.1±6.1)%和(-4.7±6.2)%,t=2.519,P=0.018];随访12个月时FVC占预计值%较基线变化值分别为[(2.3±7.0)%和(-3.3±6.2)%,t=2.292,P=0.030];D(L)CO占预计值%较基线变化值分别为[(-1.3±12.2)%和(-5.3±9.8)%,t=1.047,P= 0.303]。吡非尼酮组中17例IPF患者规律随访,治疗后6个月与治疗前6个月相比,FVC占预计值%较基线变化值分别为[(3.9±7.8)%和(-6.0 ±8.2)%,Z=-2.897,P=0.004];D(L)CO占预计值%的变化值分别为[(1.3±6.6)%和(-7.0±13.3)%,Z=-2.151,P=0.031]。分别以6个月内FVC占预计值%较基线下降≥5%或≥10%为界值进行分析,治疗后6个月患者FVC占预计值%较基线下降≥5%或≥10%的例数显著减少,差异有统计学意义(P=0.010、0.018)。吡非尼酮治疗期间30例(63.8%)出现不良反应,所有患者均未中断治疗。其中14例出现胃肠道不良反应,11例出现皮肤不良反应。 结论: 在真实世界中随访12个月,IPF患者口服吡非尼酮能够一定程度地延缓肺功能下降,对吡非尼酮耐受良好。.
引用
- Yan YJ, Fan YL, Yu SW, et al. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2018. PMID: 29747274. doi:10.3760/cma.j.issn.1001-0939.2018.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。